Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biopharmaceutical pioneer leveraging computational discovery to advance novel cancer immunotherapies. This news hub provides investors and researchers with timely updates on clinical trials, strategic partnerships, and therapeutic innovations emerging from Compugen's AI-driven platform.
Access authoritative updates on key developments including COM701 (anti-PVRIG), COM902 (anti-TIGIT), and collaborative programs with industry leaders. Our curated news collection simplifies tracking of pipeline progress, peer-reviewed research publications, and milestone achievements in immuno-oncology.
Content spans clinical trial results, regulatory milestones, and partner collaboration updates, offering a comprehensive view of Compugen's position in next-generation cancer treatment development. Bookmark this page for streamlined access to verified information about therapeutic candidates and computational discovery breakthroughs.
Compugen Ltd. (Nasdaq: CGEN) has announced that it will present new clinical data regarding its candidate COM701 during the upcoming American Society of Clinical Oncology (ASCO) annual meeting from June 2-6, 2023, in Chicago. The data will focus on the triple combination therapy of COM701, BMS-986207 (anti-TIGIT), and nivolumab in patients with metastatic endometrial cancer. The presentation titled Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab is scheduled for June 5, 2023. This research highlights Compugen's commitment to innovative cancer immunotherapy methods.
Company Background: Compugen is advancing several therapeutic programs, including COM902 and the partnered program rilvegostomig, with a focus on addressing immune resistance in cancer treatments.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
